EGFR and non-small cell lung carcinoma: For the corresponding first‐line treatment, two type I patients and six type II patients received etoposide with platinum (SCLC‐based regimen), while other two type I patients and one type II patient were treated with pemetrexed‐based chemotherapy (NSCLC‐based regimen), and one type II patient harboring EGFR exon19 del received targeted therapy‐gefitinib (NSCLC‐based regimen).